Poloxamer 184 (L64)
Based on 1 Customer Validation
Poloxamer 184 L64 is a block copolymer of polyethylene oxide and polypropylene oxide with an average molecular weight of 2900. Poloxamer has the ability to inhibit P-gp. Poloxamer 184 exhibits short-term skin toxicity, characterized by mild erythema and intradermal inflammatory reactions. Poloxamer 184 has antimicrobial activity, inhibiting 60% of Mycobacterium avium at a concentration of 1 mg/mL. Poloxamer 184 forms a thermoreversible hydrogel and is used as a food additive and as a drug delivery carrier in cosmetics and tissue engineering.
For research use only. We do not sell to patients.
- CAS No.: 9003-11-6
- Molecular Weight:2900 (Average)
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
Poloxamer 184 (1 mg/mL) can inhibit 60% of Mycobacterium avium[1].
Poloxamer has the ability to inhibit P-gp[3].
Poloxamer has been proposed as a agent carrier to improve efficacy and reduce side effects[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 9003-11-6
-
Appearance Liquid (Density: 1.095 g/cm3)
-
Molecular Weight 2900 (Average)
-
Color Colorless to light yellow
-
SMILES
[Poloxamer 184 (L64)]
-
Synonyms
PEG-PPG-PEG, 2900 (Average)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
3D Hydrogel Synthetic Scaffold Culture
3D hydrogel synthetic scaffold culture embeds cells, spheroids, organoids, or tissue fragments inside a hydrated crosslinked polymer network so that cells receive matrix and cell-cell cues in three dimensions rather than from a flat plastic surface. A literature-supported model protocol is PEG-4MAL hydrogel culture, in which four-arm maleimide-terminated PEG is functionalized with cysteine-containing adhesive peptides such as RGD and crosslinked with protease-degradable peptides such as GPQ-W; this creates a defined, modular scaffold that supports human organoid generation and culture. The readouts are scaffold-supported growth, morphology, lumen formation, budding, viability, proliferation, lineage-marker expression, and matrix-dependent expansion or differentiation; reported assays include transmitted-light imaging, immunofluorescence, in situ hybridization, qRT-PCR, and rheological characterization.
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Dermal Irritation/Dermal Toxicity Study
This protocol assesses dermal irritation using reconstructed human epidermis (RhE) models such as EpiDerm, EPISKIN, and SkinEthic RHE, in which a test substance is applied topically and tissue viability is measured after exposure; reduced viability reflects cytotoxic injury associated with skin irritation potential. The primary readout is MTT reduction, where viable cells convert tetrazolium salt into colored formazan measured by spectrophotometry; this signal is used as a quantitative viability endpoint for classifying irritant versus non-irritant responses. The historical in vivo comparator is the Draize rabbit skin irritation method, which scores erythema and edema after topical exposure, but validated RhE assays were developed to replace or reduce reliance on this animal-based endpoint.
Purity & Documentation
-
Data Sheet (266 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Singh-Joy SD, et al., Safety assessment of poloxamers 101, 105, 108, 122, 123, 124, 181, 182, 183, 184, 185, 188, 212, 215, 217, 231, 234, 235, 237, 238, 282, 284, 288, 331, 333, 334, 335, 338, 401, 402, 403, and 407, poloxamer 105 benzoate, and poloxamer 182 dibenzoate as used in cosmetics. Int J Toxicol. 2008;27 Suppl 2:93-128. [Content Brief]
[2]. Hunter RL, et al., Enhancement of antibiotic susceptibility and suppression of Mycobacterium avium complex growth by poloxamer 331. antimicrob Agents Chemother. 1995 Feb;39(2):435-9. [Content Brief]
[3]. Mello JC, et al. Enhancement of chlorpromazine antitumor activity by Pluronics F127/L81 nanostructured system against human multidrug resistant leukemia. Pharmacol Res. 2016 Sep;111:102-112. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)